うっ血性心不全(心不全):治療薬開発パイプライン動向(世界、2015年上半期版)

◆英語タイトル:Congestive Heart Failure (Heart Failure) - Pipeline Review, H1 2015
◆商品コード:GMDHC6130IDB
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2015年1月30日
◆ページ数:370
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥220,000見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD4,000 ⇒換算¥440,000見積依頼/購入/質問フォーム
Global Site License(複数国内共有可)USD6,000 ⇒換算¥660,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

当調査レポートでは、世界におけるうっ血性心不全(心不全)の治療薬開発パイプライン動向について調査・分析し、企業で開発中の治療薬、大学/研究機関で研究中の治療薬、後期段階の製品、治験段階の製品、初期段階の製品、単剤治療薬/併用治療薬/標的別/作用機序別/投与経路別/分子の種類別治療薬の評価、各薬剤のプロファイル(説明、作用機序、研究開発の進展状況)などのデータをお届けいたします。

・イントロダクション
・うっ血性心不全(心不全)の概要
・うっ血性心不全(心不全)治療薬の開発
  - パイプライン製品の概要
  - パイプライン製品の比較分析
・企業で開発中の治療薬
・大学/研究機関で研究中の治療薬
・うっ血性心不全(心不全)パイプライン製品の概略
  - 後期段階の製品
  - 治験段階の製品
  - 初期段階の製品
・製品
・大学/研究機関別、研究中の製品
・うっ血性心不全(心不全)治療薬開発に取り組んでいる企業:企業別製品パイプライン
・うっ血性心不全(心不全)治療薬の評価
  - 単剤治療薬
  - 併用治療薬
  - 標的別
  - 作用機序(MoA)別
  - 投与経路(RoA)別
  - 分子の種類別
・各薬剤のプロファイル:説明、作用機序、研究開発(R&D)の進展状況
・パイプライン製品の最新動向
・開発休止中の製品/プロジェクト
・開発が中止された製品
・製品開発のマイルストーン
【レポートの概要】

Congestive Heart Failure (Heart Failure) – Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Congestive Heart Failure (Heart Failure) – Pipeline Review, H1 2015’, provides an overview of the Congestive Heart Failure (Heart Failure)’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Congestive Heart Failure (Heart Failure), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Congestive Heart Failure (Heart Failure) and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Congestive Heart Failure (Heart Failure)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Congestive Heart Failure (Heart Failure) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Congestive Heart Failure (Heart Failure) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Congestive Heart Failure (Heart Failure) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Congestive Heart Failure (Heart Failure)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Congestive Heart Failure (Heart Failure) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Congestive Heart Failure (Heart Failure) Overview 11
Therapeutics Development 12
Pipeline Products for Congestive Heart Failure (Heart Failure) – Overview 12
Pipeline Products for Congestive Heart Failure (Heart Failure) – Comparative Analysis 13
Congestive Heart Failure (Heart Failure) – Therapeutics under Development by Companies 14
Congestive Heart Failure (Heart Failure) – Therapeutics under Investigation by Universities/Institutes 20
Congestive Heart Failure (Heart Failure) – Pipeline Products Glance 22
Late Stage Products 22
Clinical Stage Products 23
Early Stage Products 24
Congestive Heart Failure (Heart Failure) – Products under Development by Companies 25
Congestive Heart Failure (Heart Failure) – Products under Investigation by Universities/Institutes 32
Congestive Heart Failure (Heart Failure) – Companies Involved in Therapeutics Development 34
Acorda Therapeutics, Inc. 34
Amgen Inc. 35
Anexon, Inc. 36
AnGes MG, Inc. 37
Angion Biomedica Corp. 38
ARCA biopharma, Inc. 39
Ascelegen Therapeutics, Inc. 40
Asklepios BioPharmaceutical, Inc. 41
Athersys, Inc. 42
Bayer AG 43
BEAT BioTherapeutics Corp. 44
Bial – Portela & Ca, S.A. 45
Bioheart, Inc. 46
BioLineRx, Ltd. 47
Bristol-Myers Squibb Company 48
Cardio3 BioSciences SA 49
Cardioxyl Pharmaceuticals, Inc. 50
Celladon Corporation 51
Cellmid Limited 52
FibroGen, Inc. 53
GlaxoSmithKline plc 54
Glucox Biotech AB 55
Innopharmax Inc. 56
Jiangsu Hengrui Medicine Co., Ltd. 57
Juventas Therapeutics, Inc. 58
Laboratoires Pierre Fabre SA 59
Lead Pharma Holding B.V. 60
Lee’s Pharmaceutical Holdings Limited 61
Les Laboratoires Servier SAS 62
Lonestar Heart, Inc. 63
Mast Therapeutics, Inc. 64
Merck & Co., Inc. 65
Mesoblast Limited 66
Mezzion Pharma Co. Ltd. 67
MI.TO. Technology S.r.L. 68
miRagen Therapeutics, Inc. 69
NeoStem, Inc. 70
Novartis AG 71
Nyken BV 72
Ono Pharmaceutical Co., Ltd. 73
Palatin Technologies, Inc. 74
Pfizer Inc. 75
PharmaIN Corporation 76
PhaseBio Pharmaceuticals, Inc. 77
Pluristem Therapeutics Inc. 78
QUANTUM GENOMICS Corp. 79
Recardio GmbH 80
RedHill Biopharma Ltd. 81
RegenoCELL Therapeutics, Inc. 82
Sanofi 83
Stemedica Cell Technologies, Inc. 84
Target Heart Biotec Srl 85
Torrent Pharmaceuticals Limited 86
Trevena, Inc. 87
uniQure N.V. 88
Vicore Pharma AB 89
Zensun (Shanghai) Sci & Tech Co., Ltd. 90
Congestive Heart Failure (Heart Failure) – Therapeutics Assessment 91
Assessment by Monotherapy Products 91
Assessment by Combination Products 92
Assessment by Target 93
Assessment by Mechanism of Action 97
Assessment by Route of Administration 101
Assessment by Molecule Type 103
Drug Profiles 105
(sacubitril + valsartan) – Drug Profile 105
AdipoCell – Drug Profile 107
AdipoCell + MyoCell – Drug Profile 109
aladorian – Drug Profile 110
aliskiren fumarate – Drug Profile 112
AMR-001 – Drug Profile 114
ANG-3557 – Drug Profile 116
ANG-4011 – Drug Profile 117
AntimiR-199a – Drug Profile 118
ANX-042 – Drug Profile 119
ARX-720 – Drug Profile 120
BAY-1067197 – Drug Profile 121
BAY-1142524 – Drug Profile 122
BBR-12 – Drug Profile 123
beperminogene perplasmid – Drug Profile 124
BIA-51058 – Drug Profile 129
BNP-CHF – Drug Profile 130
BR-5489 – Drug Profile 131
bucindolol hydrochloride – Drug Profile 132
C-21 – Drug Profile 134
C3BSCQR-1 – Drug Profile 136
CAP-1002 – Drug Profile 138
CARD-024 – Drug Profile 140
carvedilol CR – Drug Profile 142
carvedilol CR – Drug Profile 143
carvedilol phosphate ER – Drug Profile 144
cenderitide – Drug Profile 145
CGEN-856 – Drug Profile 147
cimaglermin alfa – Drug Profile 149
CM-1 – Drug Profile 151
CMK-103 – Drug Profile 153
CTX-101 – Drug Profile 154
CTX-201 – Drug Profile 155
CXL-1036 – Drug Profile 156
CXL-1427 – Drug Profile 157
Drug for Heart Failure – Drug Profile 158
Drug to Inhibit Calpain for Heart Failure – Drug Profile 159
Drugs to Inhibit miR-425 for Hypertension and Heart Failure – Drug Profile 160
F-373280 – Drug Profile 161
FG-6874 – Drug Profile 162
FG-8205 – Drug Profile 163
finerenone – Drug Profile 164
Gene Therapy for Congestive Heart Failure – Drug Profile 165
Gene Therapy for Ischemic Heart Failure – Drug Profile 166
Gene Therapy to Activate AC-6 for Congestive Heart Failure – Drug Profile 167
Gene Therapy to Activate S100-A1 for Congestive Heart Failure – Drug Profile 168
Gene Therapy to Activate S100-A1 for Heart Failure – Drug Profile 169
Gene Therapy to Activate UCn 2 for Congestive Heart Failure – Drug Profile 170
Gene Therapy to Inhibit GRK2 for Heart Failure – Drug Profile 171
Gene Therapy to Inhibit Mef2 for Heart Failure – Drug Profile 172
GSK-2798745 – Drug Profile 173
GSK-2881078 – Drug Profile 174
istaroxime – Drug Profile 175
ITD-1 – Drug Profile 177
ivabradine – Drug Profile 178
ivabradine SR – Drug Profile 180
JVS-100 – Drug Profile 181
Mesenchymal Stem Cells – Drug Profile 183
MGN-9103 – Drug Profile 185
MicroRNAs for Heart Failure – Drug Profile 186
MK-7145 – Drug Profile 187
MP-3167 – Drug Profile 188
MPC-150IM – Drug Profile 189
MTP-131 – Drug Profile 191
MultiStem – Drug Profile 193
Mydicar – Drug Profile 196
MyoCell – Drug Profile 198
Neucardin – Drug Profile 199
NYK-1112 – Drug Profile 202
omecamtiv mecarbil – Drug Profile 203
ONO-4232 – Drug Profile 206
PB-1046 – Drug Profile 207
PGC Based Natriuretic Peptides – Drug Profile 209
PL-3994 – Drug Profile 210
poloxamer – Drug Profile 212
Protein for Diastolic Heart Failure – Drug Profile 214
pyroglutaminated serpinin – Drug Profile 215
QGC-101 – Drug Profile 216
REC-02 – Drug Profile 217
Recombinant Protein for Congestive Heart Failure – Drug Profile 218
rivaroxaban – Drug Profile 219
RNAi Gene Therapy to Inhibit STIM1 for Cardiovascular Diseases – Drug Profile 224
RNAi Oligonucleotide to Inhibit STIM1 for Cardiovascular Disorders – Drug Profile 226
S-38844 – Drug Profile 227
SAR-296968 – Drug Profile 228
serelaxin – Drug Profile 229
serpinin – Drug Profile 232
SG-1002 – Drug Profile 233
sildenafil citrate – Drug Profile 234
Small Molecule for Heart Failure-1 – Drug Profile 236
Small Molecule for Heart Failure-2 – Drug Profile 237
Small Molecule to Inhibit Beta-1 Adrenergic Receptor for Chronic Heart Failure – Drug Profile 238
Small Molecule to Inhibit BMP for Cardiovascular, CNS, Oncology and Musculoskeletal Disorders – Drug Profile 239
Small Molecule to Inhibit NOX-4 for Heart Failure – Drug Profile 240
Small Molecules for Diabetes and Congestive Heart Failure – Drug Profile 241
Small Molecules to Activate RXFP1 for Heart Failure and Fibrosis – Drug Profile 242
Small Molecules to Inhibit CaMKII for Arrhythmias and Heart Failure – Drug Profile 243
Small Molecules to Inhibit G betagamma for Heart Failure, Hypertension, Inflammation and Pain – Drug Profile 244
Small Molecules to Inhibit PDE4 for Heart Failure – Drug Profile 245
Small Molecules to Inhibit PDE5 for Ischemia Reperfusion Injury – Drug Profile 246
Small Molecules to Inversely Agonize Beta3-Adrenoreceptor for Cachexia, Metabolic Syndrome and Heart Failure – Drug Profile 247
Small Molecules to Taregt Beta 2 Adrenergic Receptor and Cannabinoid Receptor for Oncology, Respiratory and Cardiovascular Disorders – Drug Profile 248
sodium nitrite – Drug Profile 249
SP-20202 – Drug Profile 251
Stem Cell Therapy for Cardiovascular Diseases – Drug Profile 252
Stem Cell Therapy for Cardiovascular Diseases – Drug Profile 254
Stem Cell Therapy for Chronic Heart Failure – Drug Profile 255
Stem Cell Therapy for Heart failure – Drug Profile 256
Stem Cell Therapy for Heart Failure – Drug Profile 257
TRC-4186 – Drug Profile 258
TRV-027 – Drug Profile 260
TRV-120023 – Drug Profile 262
udenafil – Drug Profile 263
ularitide – Drug Profile 265
vepoloxamer – Drug Profile 266
vericiguat – Drug Profile 267
XEN-105 – Drug Profile 268
Congestive Heart Failure (Heart Failure) – Recent Pipeline Updates 269
Congestive Heart Failure (Heart Failure) – Dormant Projects 343
Congestive Heart Failure (Heart Failure) – Discontinued Products 351
Congestive Heart Failure (Heart Failure) – Product Development Milestones 353
Featured News & Press Releases 353
Appendix 361
Methodology 361
Coverage 361
Secondary Research 361
Primary Research 361
Expert Panel Validation 361
Contact Us 361
Disclaimer 362

[List of Tables]
Number of Products under Development for Congestive Heart Failure (Heart Failure), H1 2015 20
Number of Products under Development for Congestive Heart Failure (Heart Failure) - Comparative Analysis, H1 2015 21
Number of Products under Development by Companies, H1 2015 23
Number of Products under Development by Companies, H1 2015 (Contd..1) 24
Number of Products under Development by Companies, H1 2015 (Contd..2) 25
Number of Products under Development by Companies, H1 2015 (Contd..3) 26
Number of Products under Development by Companies, H1 2015 (Contd..4) 27
Number of Products under Investigation by Universities/Institutes, H1 2015 29
Comparative Analysis by Late Stage Development, H1 2015 30
Comparative Analysis by Clinical Stage Development, H1 2015 31
Comparative Analysis by Early Stage Development, H1 2015 32
Products under Development by Companies, H1 2015 33
Products under Development by Companies, H1 2015 (Contd..1) 34
Products under Development by Companies, H1 2015 (Contd..2) 35
Products under Development by Companies, H1 2015 (Contd..3) 36
Products under Development by Companies, H1 2015 (Contd..4) 37
Products under Development by Companies, H1 2015 (Contd..5) 38
Products under Development by Companies, H1 2015 (Contd..6) 39
Products under Investigation by Universities/Institutes, H1 2015 40
Products under Investigation by Universities/Institutes, H1 2015 (Contd..1) 41
Congestive Heart Failure (Heart Failure) - Pipeline by Acorda Therapeutics, Inc., H1 2015 42
Congestive Heart Failure (Heart Failure) - Pipeline by Amgen Inc., H1 2015 43
Congestive Heart Failure (Heart Failure) - Pipeline by Anexon, Inc., H1 2015 44
Congestive Heart Failure (Heart Failure) - Pipeline by AnGes MG, Inc., H1 2015 45
Congestive Heart Failure (Heart Failure) - Pipeline by Angion Biomedica Corp., H1 2015 46
Congestive Heart Failure (Heart Failure) - Pipeline by ARCA biopharma, Inc., H1 2015 47
Congestive Heart Failure (Heart Failure) - Pipeline by Ascelegen Therapeutics, Inc., H1 2015 48
Congestive Heart Failure (Heart Failure) - Pipeline by Asklepios BioPharmaceutical, Inc., H1 2015 49
Congestive Heart Failure (Heart Failure) - Pipeline by Athersys, Inc., H1 2015 50
Congestive Heart Failure (Heart Failure) - Pipeline by Bayer AG, H1 2015 51
Congestive Heart Failure (Heart Failure) - Pipeline by BEAT BioTherapeutics Corp., H1 2015 52
Congestive Heart Failure (Heart Failure) - Pipeline by Bial - Portela & Ca, S.A., H1 2015 53
Congestive Heart Failure (Heart Failure) - Pipeline by Bioheart, Inc., H1 2015 54
Congestive Heart Failure (Heart Failure) - Pipeline by BioLineRx, Ltd., H1 2015 55
Congestive Heart Failure (Heart Failure) - Pipeline by Bristol-Myers Squibb Company, H1 2015 56
Congestive Heart Failure (Heart Failure) - Pipeline by Cardio3 BioSciences SA, H1 2015 57
Congestive Heart Failure (Heart Failure) - Pipeline by Cardioxyl Pharmaceuticals, Inc., H1 2015 58
Congestive Heart Failure (Heart Failure) - Pipeline by Celladon Corporation, H1 2015 59
Congestive Heart Failure (Heart Failure) - Pipeline by Cellmid Limited, H1 2015 60
Congestive Heart Failure (Heart Failure) - Pipeline by FibroGen, Inc., H1 2015 61
Congestive Heart Failure (Heart Failure) - Pipeline by GlaxoSmithKline plc, H1 2015 62
Congestive Heart Failure (Heart Failure) - Pipeline by Glucox Biotech AB, H1 2015 63
Congestive Heart Failure (Heart Failure) - Pipeline by Innopharmax Inc., H1 2015 64
Congestive Heart Failure (Heart Failure) - Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H1 2015 65
Congestive Heart Failure (Heart Failure) - Pipeline by Juventas Therapeutics, Inc., H1 2015 66
Congestive Heart Failure (Heart Failure) - Pipeline by Laboratoires Pierre Fabre SA, H1 2015 67
Congestive Heart Failure (Heart Failure) - Pipeline by Lead Pharma Holding B.V., H1 2015 68
Congestive Heart Failure (Heart Failure) - Pipeline by Lee's Pharmaceutical Holdings Limited, H1 2015 69
Congestive Heart Failure (Heart Failure) - Pipeline by Les Laboratoires Servier SAS, H1 2015 70
Congestive Heart Failure (Heart Failure) - Pipeline by Lonestar Heart, Inc., H1 2015 71
Congestive Heart Failure (Heart Failure) - Pipeline by Mast Therapeutics, Inc., H1 2015 72
Congestive Heart Failure (Heart Failure) - Pipeline by Merck & Co., Inc., H1 2015 73
Congestive Heart Failure (Heart Failure) - Pipeline by Mesoblast Limited, H1 2015 74
Congestive Heart Failure (Heart Failure) - Pipeline by Mezzion Pharma Co. Ltd., H1 2015 75
Congestive Heart Failure (Heart Failure) - Pipeline by MI.TO. Technology S.r.L., H1 2015 76
Congestive Heart Failure (Heart Failure) - Pipeline by miRagen Therapeutics, Inc., H1 2015 77
Congestive Heart Failure (Heart Failure) - Pipeline by NeoStem, Inc., H1 2015 78
Congestive Heart Failure (Heart Failure) - Pipeline by Novartis AG, H1 2015 79
Congestive Heart Failure (Heart Failure) - Pipeline by Nyken BV, H1 2015 80
Congestive Heart Failure (Heart Failure) - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2015 81
Congestive Heart Failure (Heart Failure) - Pipeline by Palatin Technologies, Inc., H1 2015 82
Congestive Heart Failure (Heart Failure) - Pipeline by Pfizer Inc., H1 2015 83
Congestive Heart Failure (Heart Failure) - Pipeline by PharmaIN Corporation, H1 2015 84
Congestive Heart Failure (Heart Failure) - Pipeline by PhaseBio Pharmaceuticals, Inc., H1 2015 85
Congestive Heart Failure (Heart Failure) - Pipeline by Pluristem Therapeutics Inc., H1 2015 86
Congestive Heart Failure (Heart Failure) - Pipeline by QUANTUM GENOMICS Corp., H1 2015 87
Congestive Heart Failure (Heart Failure) - Pipeline by Recardio GmbH, H1 2015 88
Congestive Heart Failure (Heart Failure) - Pipeline by RedHill Biopharma Ltd., H1 2015 89
Congestive Heart Failure (Heart Failure) - Pipeline by RegenoCELL Therapeutics, Inc., H1 2015 90
Congestive Heart Failure (Heart Failure) - Pipeline by Sanofi, H1 2015 91
Congestive Heart Failure (Heart Failure) - Pipeline by Stemedica Cell Technologies, Inc., H1 2015 92
Congestive Heart Failure (Heart Failure) - Pipeline by Target Heart Biotec Srl, H1 2015 93
Congestive Heart Failure (Heart Failure) - Pipeline by Torrent Pharmaceuticals Limited, H1 2015 94
Congestive Heart Failure (Heart Failure) - Pipeline by Trevena, Inc., H1 2015 95
Congestive Heart Failure (Heart Failure) - Pipeline by uniQure N.V., H1 2015 96
Congestive Heart Failure (Heart Failure) - Pipeline by Vicore Pharma AB, H1 2015 97
Congestive Heart Failure (Heart Failure) - Pipeline by Zensun (Shanghai) Sci & Tech Co., Ltd., H1 2015 98
Assessment by Monotherapy Products, H1 2015 99
Assessment by Combination Products, H1 2015 100
Number of Products by Stage and Target, H1 2015 102
Number of Products by Stage and Mechanism of Action, H1 2015 106
Number of Products by Stage and Route of Administration, H1 2015 110
Number of Products by Stage and Molecule Type, H1 2015 112
Congestive Heart Failure (Heart Failure) Therapeutics - Recent Pipeline Updates, H1 2015 277
Congestive Heart Failure (Heart Failure) - Dormant Projects, H1 2015 351
Congestive Heart Failure (Heart Failure) - Dormant Projects (Contd..1), H1 2015 352
Congestive Heart Failure (Heart Failure) - Dormant Projects (Contd..2), H1 2015 353
Congestive Heart Failure (Heart Failure) - Dormant Projects (Contd..3), H1 2015 354
Congestive Heart Failure (Heart Failure) - Dormant Projects (Contd..4), H1 2015 355
Congestive Heart Failure (Heart Failure) - Dormant Projects (Contd..5), H1 2015 356
Congestive Heart Failure (Heart Failure) - Dormant Projects (Contd..6), H1 2015 357
Congestive Heart Failure (Heart Failure) - Dormant Projects (Contd..7), H1 2015 358
Congestive Heart Failure (Heart Failure) - Discontinued Products, H1 2015 359
Congestive Heart Failure (Heart Failure) - Discontinued Products (Contd..1), H1 2015 360

[List of Figures]
Number of Products under Development for Congestive Heart Failure (Heart Failure), H1 2015 20
Number of Products under Development for Congestive Heart Failure (Heart Failure) - Comparative Analysis, H1 2015 21
Number of Products under Development by Companies, H1 2015 22
Number of Products under Investigation by Universities/Institutes, H1 2015 28
Comparative Analysis by Late Stage Development, H1 2015 30
Comparative Analysis by Clinical Stage Development, H1 2015 31
Comparative Analysis by Early Stage Products, H1 2015 32
Assessment by Monotherapy Products, H1 2015 99
Assessment by Combination Products, H1 2015 100
Number of Products by Top 10 Targets, H1 2015 101
Number of Products by Stage and Top 10 Targets, H1 2015 101
Number of Products by Top 10 Mechanism of Actions, H1 2015 105
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 105
Number of Products by Top 10 Routes of Administration, H1 2015 109
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 110
Number of Products by Top 10 Molecule Types, H1 2015 111
Number of Products by Stage and Top 10 Molecule Types, H1 2015 111

【掲載企業】

Acorda Therapeutics, Inc.
Amgen Inc.
Anexon, Inc.
AnGes MG, Inc.
Angion Biomedica Corp.
ARCA biopharma, Inc.
Ascelegen Therapeutics, Inc.
Asklepios BioPharmaceutical, Inc.
Athersys, Inc.
Bayer AG
BEAT BioTherapeutics Corp.
Bial - Portela & Ca, S.A.
Bioheart, Inc.
BioLineRx, Ltd.
Bristol-Myers Squibb Company
Cardio3 BioSciences SA
Cardioxyl Pharmaceuticals, Inc.
Celladon Corporation
Cellmid Limited
FibroGen, Inc.
GlaxoSmithKline plc
Glucox Biotech AB
Innopharmax Inc.
Jiangsu Hengrui Medicine Co., Ltd.
Juventas Therapeutics, Inc.
Laboratoires Pierre Fabre SA
Lead Pharma Holding B.V.
Lee's Pharmaceutical Holdings Limited
Les Laboratoires Servier SAS
Lonestar Heart, Inc.
Mast Therapeutics, Inc.
Merck & Co., Inc.
Mesoblast Limited
Mezzion Pharma Co. Ltd.
MI.TO. Technology S.r.L.
miRagen Therapeutics, Inc.
NeoStem, Inc.
Novartis AG
Nyken BV
Ono Pharmaceutical Co., Ltd.
Palatin Technologies, Inc.
Pfizer Inc.
PharmaIN Corporation
PhaseBio Pharmaceuticals, Inc.
Pluristem Therapeutics Inc.
QUANTUM GENOMICS Corp.
Recardio GmbH
RedHill Biopharma Ltd.
RegenoCELL Therapeutics, Inc.
Sanofi
Stemedica Cell Technologies, Inc.
Target Heart Biotec Srl
Torrent Pharmaceuticals Limited
Trevena, Inc.
uniQure N.V.
Vicore Pharma AB
Zensun (Shanghai) Sci & Tech Co., Ltd.

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[うっ血性心不全(心不全):治療薬開発パイプライン動向(世界、2015年上半期版)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆